FLYSYN

Drug Profile

FLYSYN

Alternative Names: 4G8-SDIEM

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synimmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 01 Feb 2017 Phase-I/II clinical trials in Acute myeloid leukaemia (Monotherapy) in Germany (IV) (NCT02789254)
  • 13 May 2016 Synimmune plans a phase Ib/IIa trial for Acute myeloid leukaemia in Germany (NCT02789254)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top